Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)
Peter A. LeWitt, M. Guttman, James W. Tetrud, Paul J. Tuite, Akihisa Mori, Philip Chaikin, Neil M. SussmanVolume:
63
Year:
2008
Language:
english
Pages:
8
DOI:
10.1002/ana.21315
File:
PDF, 146 KB
english, 2008